Simultaneous Quantitation of Anlotinib and Osimertinib by Isotope-Labeled UHPLC–MS/MS in Human Plasma: Application in NSCLC Patients
Journal of Chromatographic Science · 2024
DOI: 10.1093/chromsci/bmad024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Chromatographic Science, 2024. Verfasst von Yao Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, PR China. Hauptthemen laut MEDLINE: Quinolines, Tandem Mass Spectrometry, Aniline Compounds, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Fund of the Fifth Hospital of Sun-Yat sen University, Pharmaceutical Research Special Fund of Guangdong Hospital Association (Hengrui).
Abstract (Originalsprache)
Anlotinib and osimertinib are a class of tyrosine kinase inhibitors for the treatment of malignant tumor. The combination of anlotinib and osimertinib is currently used for treating non-small cell lung cancer (NSCLC) patients. This study aimed to develop a simple and rapid isotope-labeled UHPLC–MS/MS method for the simultaneous determination of anlotinib and osimertinib in human plasma. The analytes were extracted by protein precipitation with acetonitrile and were then separated on a Shim-pack GIST C18 column. The detection was performed on Shimadzu 8050 triple quadruple mass spectrometer in the positive electrospray ionization mode with multiple reaction monitoring. The precursor-to-product ion transitions were m/z 408.10→ 339.75, 500.25→ 72.20 and 413.50 → 344.50 for anlotinib, osimertinib and D5-anlotinib, respectively. Validation is based on US Food and Drug Administration guidelines. The linearity ranges were 0.5–100 ng/mL for anlotinib and were 1–500 ng/mL for osimertinib with the correlation coefficients (r 2) ≥ 0.99. Accuracy and precision, matrix effect, extraction recovery and stability of anlotinib and osimertinib were acceptable after validation. The UHPLC–MS/MS method was successfully validated and was applied to monitor the concentration of anlotinib and osimertinib in NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, PR China.
- Department of Thoracic Oncology, Cancer Center, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, PR China.
- Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, North Campus, Sun Yat-Sen University, Guangzhou 510080, PR China.
Förderung
- Fund of the Fifth Hospital of Sun-Yat sen University
- Pharmaceutical Research Special Fund of Guangdong Hospital Association (Hengrui)
Zitieren
APA
Liu, Y., Lin, Z., Luo, W., Pei, X., She, Z., Sha, Z., Guan, Y., Ming, D., & Liang, J. (2024). Simultaneous Quantitation of Anlotinib and Osimertinib by Isotope-Labeled UHPLC–MS/MS in Human Plasma: Application in NSCLC Patients. Journal of Chromatographic Science. https://doi.org/10.1093/chromsci/bmad024
Vancouver
Liu Y, Lin Z, Luo W, Pei X, She Z, Sha Z, et al. Simultaneous Quantitation of Anlotinib and Osimertinib by Isotope-Labeled UHPLC–MS/MS in Human Plasma: Application in NSCLC Patients. Journal of Chromatographic Science. 2024. doi:10.1093/chromsci/bmad024
BibTeX
@article{Liu2024,
author = {Liu, Yao and Lin, Zhong and Luo, Wenji and Pei, Xiaofeng and She, Ziyue and Sha, Zhou and Guan, Yanping and Ming, Dandan and Liang, Jiabi},
title = {Simultaneous Quantitation of Anlotinib and Osimertinib by Isotope-Labeled UHPLC–MS/MS in Human Plasma: Application in NSCLC Patients},
journal = {Journal of Chromatographic Science},
year = {2024},
doi = {10.1093/chromsci/bmad024}
}
EUVIMED